ERBB2 and breast carcinoma: (Louis et al., 2021) AGAP2-AS1 could be promising predictive biomarker and therapeutic target for HER-2+ breast cancer patients (Han et al., 2021), and AGAP2-AS1 regulated the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4 (Hui et al., 2019).